Atherosclerosis- A Brief Review




                Biochemistry for Medics
                www.namrata.co
11/15/2012       Biochemistry for Medics   1
Normal Blood Vessel Wall
• Vessel walls are
  organized into three
  concentric layers:
  intima, media, and
  adventitia
• These are present to
  some extent in all
  vessels but are most
  apparent in larger
  arteries and veins.

11/15/2012          Biochemistry for Medics   2
Normal Blood Vessel Wall
Blood vessel walls
1. The three tunics:
a) Tunica intima
(1) Endothelium
(2) Subendothelial layer
b) Tunica media
(1) Smooth muscle
(2) Elastin
c) Tunica adventitia (externa)
(1) CT(Connective tissue) surrounding TM(Tunica Media)
(2) Arterioles in larger vessels

11/15/2012              Biochemistry for Medics          3
Normal Blood Vessel Wall




11/15/2012   Biochemistry for Medics   4
Normal Blood Vessel Wall
• Arterial walls are
  thicker than
  corresponding
  veins at the same
  level of branching
  to accommodate
  pulsatile flow and
  higher blood
  pressure.

  11/15/2012           Biochemistry for Medics   5
Classes of Arteries
Arteries
a) Elastic arteries – large arteries near heart
b) Muscular (distributing) arteries – thick tunica
   media
c) Arterioles- Diameter regulated by
   vasoconstriction/dilation
Atherosclerosis affects mainly elastic and muscular
arteries and hypertension affects small muscular
arteries and arterioles.

11/15/2012          Biochemistry for Medics       6
Atherosclerosis
Atherosclerosis is a disease of large and
 medium-sized muscular arteries and is
 characterized by –
endothelial dysfunction,
vascular inflammation, and
the buildup of lipids, cholesterol, calcium, and
 cellular debris within the intima of the vessel
 wall.

11/15/2012          Biochemistry for Medics         7
Atherosclerosis

 It is characterized by
 intimal lesions called
 atheromas (also called
 Atheromatous or
 atherosclerotic
 plaques), that
 protrude into vascular
 lumina.


11/15/2012            Biochemistry for Medics   8
Atheromatous plaque

     An Atheromatous plaque consists of a
     raised lesion with a soft, yellow, grumous core
     of lipid (mainly cholesterol and cholesterol
     esters) covered by a firm, white fibrous cap.
     Besides obstructing blood
     flow, atherosclerotic plaques weaken the
     underlying media and can themselves
     rupture, causing acute thrombosis.

11/15/2012              Biochemistry for Medics        9
Atheromatous plaque




  Atherosclerosis or Arteriosclerosis is a slow and
  progressive building up of plaque, fatty
  substances, cholesterol, cellular waste
  products, calcium andBiochemistry forin the inner lining of
11/15/2012               fibrin Medics                          10
Atherosclerosis
Atherosclerosis primarily affects elastic
 arteries (e.g., aorta, carotid, and iliac arteries)
Large and medium-sized muscular arteries
 (e.g., coronary and popliteal arteries).
In small arteries, atheromas can gradually
 occlude lumina, compromising blood flow to
 distal organs and cause ischemic injury.


11/15/2012           Biochemistry for Medics           11
Atherosclerosis




 Atherosclerosis also takes a toll through other
  consequences of acutely or chronically diminished arterial
  perfusion, such as mesenteric occlusion, sudden cardiac
  death, chronic IHD, and ischemic encephalopathy.

11/15/2012               Biochemistry for Medics               12
Risk Factors for Atherosclerosis
Major risk factors (Non Modifiable)-
 Increasing Age
 Male gender
 Family history
 Genetic abnormalities




11/15/2012         Biochemistry for Medics   13
Risk Factors for Atherosclerosis
Lesser, Uncertain, or Nonquantitated Risks-
Obesity
Physical Inactivity
Postmenopausal estrogen deficiency
High carbohydrate intake
Lipoprotein(a)
Hardened (trans)unsaturated fat intake
Chlamydia pneumoniae infection

11/15/2012         Biochemistry for Medics    14
Risk Factors for Atherosclerosis
Potentially Controllable-
 Hyperlipidemia
Hypertension
Cigarette smoking
Diabetes
C-reactive protein



11/15/2012         Biochemistry for Medics   15
Age as a risk factor
Age is a dominant influence.
Although the accumulation of atherosclerotic
 plaque is typically a progressive process, it does
 not usually become clinically manifest until
 lesions reach a critical threshold and begin to
 precipitate organ injury in middle age or later.
Thus, between ages 40 and 60, the incidence of
 myocardial infarction in men increases fivefold
Death rates from IHD rise with each decade even
 into advanced age.
11/15/2012           Biochemistry for Medics          16
Gender
Premenopausal women are relatively protected
 against atherosclerosis and its consequences
 compared with age-matched men
Myocardial infarction and other complications of
 atherosclerosis are uncommon in premenopausal
 women unless otherwise predisposed by
 diabetes, hyperlipidemia, or severe hypertension.
After menopause, the incidence of
 atherosclerosis-related diseases increases and
 with greater age exceeds that of men.
11/15/2012          Biochemistry for Medics      17
Genetics
The familial predisposition to atherosclerosis
 and IHD is multifactorial.
In some instances it relates to familial
 clustering of other risk factors, such as
 hypertension or diabetes
In others it involves well-defined genetic
 derangements in lipoprotein metabolism, such
 as familial hypercholesterolemia that result in
 excessively high blood lipid levels.

11/15/2012         Biochemistry for Medics     18
Hyperlipidemia
Hyperlipidemia-more
 specifically, hypercholesterolemia-is a major risk
 factor for atherosclerosis;
Even in the absence of other risk
 factors, hypercholesterolemia is sufficient to
 stimulate lesion development.
The major component of serum cholesterol
 associated with increased risk is low-density
 lipoprotein (LDL) cholesterol ("bad cholesterol")
11/15/2012           Biochemistry for Medics          19
Hyperlipidemia
LDL cholesterol has an essential physiologic role
 delivering cholesterol to peripheral tissues.
In contrast, high-density lipoprotein (HDL, "good
 cholesterol") mobilizes cholesterol from
 developing and existing atheromas and
 transports it to the liver for excretion in the bile.
Consequently, higher levels of HDL correlate with
 reduced risk.


11/15/2012            Biochemistry for Medics        20
Factors affecting plasma lipid levels
High dietary intake of cholesterol and saturated
 fats (present in egg yolks, animal fats, and
 butter, for example) raises plasma cholesterol
 levels.
Diets low in cholesterol and/or with higher ratios
 of polyunsaturated fats lower plasma cholesterol
 levels.
Omega-3 fatty acids (abundant in fish oils) are
 beneficial, whereas (trans)unsaturated fats
 produced by artificial hydrogenation of
 polyunsaturated oils (used in baked goods and
 margarine) adversely affect cholesterol profiles.
11/15/2012           Biochemistry for Medics          21
Factors affecting plasma lipid levels
Exercise and moderate consumption of
 ethanol both raise HDL levels, whereas obesity
 and smoking lower it.
 Statins are a class of drugs that lower
 circulating cholesterol levels by inhibiting
 hydroxy methylglutaryl coenzyme A
 reductase, the rate-limiting enzyme in hepatic
 cholesterol biosynthesis.

11/15/2012         Biochemistry for Medics    22
Hypertension
On its own, hypertension can increase the risk
 of IHD by approximately 60% in comparison
 with normotensive populations
Left untreated, roughly half of hypertensive
 patients will die of IHD or congestive heart
 failure, and another third will die of stroke.



11/15/2012         Biochemistry for Medics    23
Cigarette Smoking
Cigarette smoking is a well-established risk factor
 in men
An increase in the number of women who smoke
 probably accounts for the increasing incidence
 and severity of atherosclerosis in women.
Prolonged (years) smoking of one pack of
 cigarettes or more daily increases the death rate
 from IHD by 200%.
Smoking cessation reduces that risk substantially.
11/15/2012           Biochemistry for Medics       24
Diabetes Mellitus
Diabetes mellitus induces
 hypercholesterolemia as well as a markedly
 increased predisposition to atherosclerosis.
Other factors being equal, the incidence of
 myocardial infarction is twice as high in
 diabetic as in Nondiabetic individuals.
There is also an increased risk of strokes and a
 100-fold increased risk of atherosclerosis-
 induced gangrene of the lower extremities.

11/15/2012          Biochemistry for Medics     25
Additional Risk Factors
Despite the identification of
 hypertension, diabetes, smoking, and
 hyperlipidemia as major risk factors, as many
 as 20% of all cardiovascular events occur in
 the absence of any of these.
other "nontraditional" factors contribute to
 risk.


11/15/2012         Biochemistry for Medics       26
Lipoprotein a or Lp(a)
Lipoprotein a or Lp(a), is an altered form of
 LDL that contains the apolipoprotein B-100
 portion of LDL linked to apolipoprotein A;
Increased Lp(a) levels are associated with a
 higher risk of coronary and cerebro vascular
 disease, independent of total cholesterol or
 LDL levels.


11/15/2012         Biochemistry for Medics       27
Additional Risk Factors
 Stressful lifestyle ("type A" personality);
 Obesity - Due to
o Hypertension
o Diabetes
o Hypertriglyceridemia and
o Decreased HDL.



11/15/2012           Biochemistry for Medics    28
Pathogenesis of Atherosclerosis
The contemporary view of atherogenesis is
 expressed by the response-to-injury hypothesis.
This model views atherosclerosis as a chronic
 inflammatory response of the arterial wall to
 endothelial injury.
 Lesion progression occurs through interactions of
 modified lipoproteins, monocyte-derived
 macrophages, T lymphocytes, and the normal
 cellular constituents of the arterial wall.
11/15/2012          Biochemistry for Medics       29
Pathogenesis of Atherosclerosis
1) Endothelial Injury
     Initial triggering event in the development of
      Atherosclerotic lesions
     Causes ascribed to endothelial injury in include
      mechanical trauma, hemodynamic
      forces, immunological and chemical
      mechanisms, metabolic agents like chronic
      hyperlipidemia, homocystine, circulating toxins
      from systemic infections, viruses, and tobacco
      products.
11/15/2012             Biochemistry for Medics           30
Pathogenesis of Atherosclerosis
2. Intimal Smooth Muscle Cell Proliferation
     Endothelial injury causes adherence aggregation and
      platelet release reaction at the site of exposed sub
      endothelial connective tissue.
     Proliferation of intimal smooth muscle cells is
      stimulated by various mitogens released from
      platelets adherent at the site of endothelial injury.
     These mitogens include platelet derived growth
      factor (PDGF), fibroblast growth factor, TNF-ÎŹ.
     Proliferation is also facilitated by nitric oxide and
      endothelin released from endothelial cells.

11/15/2012               Biochemistry for Medics          31
Pathogenesis of Atherosclerosis
3) Role of Blood Monocytes
      Though blood monocytes do not possess
       receptors for normal LDL, LDL does appear in the
       monocyte cytoplasm to form foam cell.
      Plasma LDL on entry into the intima undergoes
       oxidation.
      Oxidized LDL formed in the intima is readily taken
       up by scavenger receptor on the monocyte to
       transform it to a lipid laden foam cell.

11/15/2012               Biochemistry for Medics        32
11/15/2012   Biochemistry for Medics   33
Pathogenesis of Atherosclerosis
Oxidized LDL stimulates the release of growth
 factors, cytokines, and chemokines by
 endothelial cells (EC)and macrophages that
 increase monocyte recruitment into lesions.
Oxidized LDL is cytotoxic to ECs and smooth
 muscle cells (SMCs )and can induce
 Endothelial dysfunction.


11/15/2012         Biochemistry for Medics       34
Pathogenesis of Atherosclerosis
4) Role of Hyperlipidemia
Chronic hyperlipidemia in itself may initiate
  endothelial injury and dysfunction by causing
  increased permeability.
 Increased serum concentration of LDL and
  VLDL promote formation of foam cells, while
  high serum concentration of HDL has anti-
  atherogenic effect.

11/15/2012         Biochemistry for Medics        35
11/15/2012   Biochemistry for Medics   36
Progression of Atherosclerosis
 Fatty Streaks- Fatty streaks are composed of lipid-filled
  foam cells but are not significantly raised and thus do
  not cause any disturbance in blood flow
 Fatty streaks can appear in the aortas of infants
  younger than 1 year and are present in virtually all
  children older than 10 years, regardless of
  geography, race, sex, or environment.
 The relationship of fatty streaks to atherosclerotic
  plaques is uncertain; although they may evolve into
  precursors of plaques, not all fatty streaks are destined
  to become advanced atherosclerotic lesions.

11/15/2012              Biochemistry for Medics           37
Progression of Atherosclerosis
Atherosclerotic Plaque-The key processes in
  atherosclerosis are intimal thickening and lipid
  accumulation Atheromatous plaques (also
  called fibrous or fibro fatty plaques) impinge
  on the lumen of the artery and grossly appear
  white to yellow
Plaques vary from 0.3 to 1.5 cm in diameter but
  can coalesce to form larger masses.

11/15/2012          Biochemistry for Medics      38
Components of Atherosclerotic
plaque
 Atherosclerotic plaques have three principal
 components:
Cells, including SMCs, macrophages, and T cells
 ECM, including collagen, elastic fibers, and
 proteoglycans and
Intracellular and extracellular lipid
These components occur in varying proportions
 and configurations in different lesions.

11/15/2012          Biochemistry for Medics        39
Changes in Atherosclerotic Plaque
Atherosclerotic plaques are susceptible to the following
  pathologic changes with clinical significance:
 Rupture, ulceration, or erosion
 Hemorrhage
 Atheroembolism
 Aneurysm formation
 Atherosclerosis is a slowly evolving lesion usually requiring
  many decades to become significant.
 However, acute plaque changes
  (e.g., rupture, thrombosis, or hematoma formation) can
  rapidly precipitate clinical sequelae (the so-called "clinical
  horizon“)

11/15/2012                Biochemistry for Medics                  40
Progression of Atherosclerosis




11/15/2012    Biochemistry for Medics   41
Atherosclerosis- Symptoms
Symptomatic atherosclerotic disease most
 often involves the arteries supplying the
 heart, brain, kidneys, and lower extremities.
Myocardial infarction (heart attack), cerebral
 infarction (stroke), aortic aneurysms, and
 peripheral vascular disease (gangrene of the
 legs) are the major consequences of
 atherosclerosis.

11/15/2012         Biochemistry for Medics        42
Prevention of Atherosclerotic Vascular
Disease
Primary prevention aims at either delaying
  atheroma formation or encouraging
  regression of established lesions in persons
  who have not yet suffered a serious
  complication of atherosclerosis
Secondary prevention is intended to prevent
  recurrence of events such as myocardial
  infarction or stroke in symptomatic patients

11/15/2012         Biochemistry for Medics       43
Prevention of Atherosclerotic
Vascular Disease
Primary prevention of atherosclerosis
 Cessation of cigarette smoking
 Control of hypertension
 Weight loss
 Exercise, and lowering total and LDL blood cholesterol
  levels while increasing HDL (e.g., by diet or through
  statins).
 Statin use may also modulate the inflammatory state of
  the vascular wall.
 Risk factor stratification and reduction should even
  begin in childhood.

11/15/2012            Biochemistry for Medics         44
Prevention of Atherosclerotic
Vascular Disease
Secondary prevention involves use of –
Aspirin (anti-platelet agent),
Statins, and beta blockers (to limit cardiac
  demand),
Surgical interventions (e.g., coronary artery
  bypass surgery, carotid endarterectomy).
These can successfully reduce recurrent
  myocardial or cerebral events.
11/15/2012          Biochemistry for Medics      45
Summary
 Atherosclerosis is an intima-based lesion organized into
  a fibrous cap and an atheromatous (gruel-like) core and
  composed of SMCs, ECM, inflammatory
  cells, lipids, and necrotic debris.
 Atherogenesis is driven by an interplay of inflammation
  and injury to vessel wall cells.
 Atherosclerotic plaques accrue slowly over decades but
  may acutely cause symptoms due to
  rupture, thrombosis, hemorrhage, or embolization.
 Risk factor recognition and reduction can reduce the
  incidence and severity of atherosclerosis-related
  disease.

11/15/2012             Biochemistry for Medics          46

Atherosclerosis

  • 1.
    Atherosclerosis- A BriefReview Biochemistry for Medics www.namrata.co 11/15/2012 Biochemistry for Medics 1
  • 2.
    Normal Blood VesselWall • Vessel walls are organized into three concentric layers: intima, media, and adventitia • These are present to some extent in all vessels but are most apparent in larger arteries and veins. 11/15/2012 Biochemistry for Medics 2
  • 3.
    Normal Blood VesselWall Blood vessel walls 1. The three tunics: a) Tunica intima (1) Endothelium (2) Subendothelial layer b) Tunica media (1) Smooth muscle (2) Elastin c) Tunica adventitia (externa) (1) CT(Connective tissue) surrounding TM(Tunica Media) (2) Arterioles in larger vessels 11/15/2012 Biochemistry for Medics 3
  • 4.
    Normal Blood VesselWall 11/15/2012 Biochemistry for Medics 4
  • 5.
    Normal Blood VesselWall • Arterial walls are thicker than corresponding veins at the same level of branching to accommodate pulsatile flow and higher blood pressure. 11/15/2012 Biochemistry for Medics 5
  • 6.
    Classes of Arteries Arteries a)Elastic arteries – large arteries near heart b) Muscular (distributing) arteries – thick tunica media c) Arterioles- Diameter regulated by vasoconstriction/dilation Atherosclerosis affects mainly elastic and muscular arteries and hypertension affects small muscular arteries and arterioles. 11/15/2012 Biochemistry for Medics 6
  • 7.
    Atherosclerosis Atherosclerosis is adisease of large and medium-sized muscular arteries and is characterized by – endothelial dysfunction, vascular inflammation, and the buildup of lipids, cholesterol, calcium, and cellular debris within the intima of the vessel wall. 11/15/2012 Biochemistry for Medics 7
  • 8.
    Atherosclerosis It ischaracterized by intimal lesions called atheromas (also called Atheromatous or atherosclerotic plaques), that protrude into vascular lumina. 11/15/2012 Biochemistry for Medics 8
  • 9.
    Atheromatous plaque An Atheromatous plaque consists of a raised lesion with a soft, yellow, grumous core of lipid (mainly cholesterol and cholesterol esters) covered by a firm, white fibrous cap. Besides obstructing blood flow, atherosclerotic plaques weaken the underlying media and can themselves rupture, causing acute thrombosis. 11/15/2012 Biochemistry for Medics 9
  • 10.
    Atheromatous plaque Atherosclerosis or Arteriosclerosis is a slow and progressive building up of plaque, fatty substances, cholesterol, cellular waste products, calcium andBiochemistry forin the inner lining of 11/15/2012 fibrin Medics 10
  • 11.
    Atherosclerosis Atherosclerosis primarily affectselastic arteries (e.g., aorta, carotid, and iliac arteries) Large and medium-sized muscular arteries (e.g., coronary and popliteal arteries). In small arteries, atheromas can gradually occlude lumina, compromising blood flow to distal organs and cause ischemic injury. 11/15/2012 Biochemistry for Medics 11
  • 12.
    Atherosclerosis  Atherosclerosis alsotakes a toll through other consequences of acutely or chronically diminished arterial perfusion, such as mesenteric occlusion, sudden cardiac death, chronic IHD, and ischemic encephalopathy. 11/15/2012 Biochemistry for Medics 12
  • 13.
    Risk Factors forAtherosclerosis Major risk factors (Non Modifiable)-  Increasing Age  Male gender  Family history  Genetic abnormalities 11/15/2012 Biochemistry for Medics 13
  • 14.
    Risk Factors forAtherosclerosis Lesser, Uncertain, or Nonquantitated Risks- Obesity Physical Inactivity Postmenopausal estrogen deficiency High carbohydrate intake Lipoprotein(a) Hardened (trans)unsaturated fat intake Chlamydia pneumoniae infection 11/15/2012 Biochemistry for Medics 14
  • 15.
    Risk Factors forAtherosclerosis Potentially Controllable-  Hyperlipidemia Hypertension Cigarette smoking Diabetes C-reactive protein 11/15/2012 Biochemistry for Medics 15
  • 16.
    Age as arisk factor Age is a dominant influence. Although the accumulation of atherosclerotic plaque is typically a progressive process, it does not usually become clinically manifest until lesions reach a critical threshold and begin to precipitate organ injury in middle age or later. Thus, between ages 40 and 60, the incidence of myocardial infarction in men increases fivefold Death rates from IHD rise with each decade even into advanced age. 11/15/2012 Biochemistry for Medics 16
  • 17.
    Gender Premenopausal women arerelatively protected against atherosclerosis and its consequences compared with age-matched men Myocardial infarction and other complications of atherosclerosis are uncommon in premenopausal women unless otherwise predisposed by diabetes, hyperlipidemia, or severe hypertension. After menopause, the incidence of atherosclerosis-related diseases increases and with greater age exceeds that of men. 11/15/2012 Biochemistry for Medics 17
  • 18.
    Genetics The familial predispositionto atherosclerosis and IHD is multifactorial. In some instances it relates to familial clustering of other risk factors, such as hypertension or diabetes In others it involves well-defined genetic derangements in lipoprotein metabolism, such as familial hypercholesterolemia that result in excessively high blood lipid levels. 11/15/2012 Biochemistry for Medics 18
  • 19.
    Hyperlipidemia Hyperlipidemia-more specifically, hypercholesterolemia-isa major risk factor for atherosclerosis; Even in the absence of other risk factors, hypercholesterolemia is sufficient to stimulate lesion development. The major component of serum cholesterol associated with increased risk is low-density lipoprotein (LDL) cholesterol ("bad cholesterol") 11/15/2012 Biochemistry for Medics 19
  • 20.
    Hyperlipidemia LDL cholesterol hasan essential physiologic role delivering cholesterol to peripheral tissues. In contrast, high-density lipoprotein (HDL, "good cholesterol") mobilizes cholesterol from developing and existing atheromas and transports it to the liver for excretion in the bile. Consequently, higher levels of HDL correlate with reduced risk. 11/15/2012 Biochemistry for Medics 20
  • 21.
    Factors affecting plasmalipid levels High dietary intake of cholesterol and saturated fats (present in egg yolks, animal fats, and butter, for example) raises plasma cholesterol levels. Diets low in cholesterol and/or with higher ratios of polyunsaturated fats lower plasma cholesterol levels. Omega-3 fatty acids (abundant in fish oils) are beneficial, whereas (trans)unsaturated fats produced by artificial hydrogenation of polyunsaturated oils (used in baked goods and margarine) adversely affect cholesterol profiles. 11/15/2012 Biochemistry for Medics 21
  • 22.
    Factors affecting plasmalipid levels Exercise and moderate consumption of ethanol both raise HDL levels, whereas obesity and smoking lower it.  Statins are a class of drugs that lower circulating cholesterol levels by inhibiting hydroxy methylglutaryl coenzyme A reductase, the rate-limiting enzyme in hepatic cholesterol biosynthesis. 11/15/2012 Biochemistry for Medics 22
  • 23.
    Hypertension On its own,hypertension can increase the risk of IHD by approximately 60% in comparison with normotensive populations Left untreated, roughly half of hypertensive patients will die of IHD or congestive heart failure, and another third will die of stroke. 11/15/2012 Biochemistry for Medics 23
  • 24.
    Cigarette Smoking Cigarette smokingis a well-established risk factor in men An increase in the number of women who smoke probably accounts for the increasing incidence and severity of atherosclerosis in women. Prolonged (years) smoking of one pack of cigarettes or more daily increases the death rate from IHD by 200%. Smoking cessation reduces that risk substantially. 11/15/2012 Biochemistry for Medics 24
  • 25.
    Diabetes Mellitus Diabetes mellitusinduces hypercholesterolemia as well as a markedly increased predisposition to atherosclerosis. Other factors being equal, the incidence of myocardial infarction is twice as high in diabetic as in Nondiabetic individuals. There is also an increased risk of strokes and a 100-fold increased risk of atherosclerosis- induced gangrene of the lower extremities. 11/15/2012 Biochemistry for Medics 25
  • 26.
    Additional Risk Factors Despitethe identification of hypertension, diabetes, smoking, and hyperlipidemia as major risk factors, as many as 20% of all cardiovascular events occur in the absence of any of these. other "nontraditional" factors contribute to risk. 11/15/2012 Biochemistry for Medics 26
  • 27.
    Lipoprotein a orLp(a) Lipoprotein a or Lp(a), is an altered form of LDL that contains the apolipoprotein B-100 portion of LDL linked to apolipoprotein A; Increased Lp(a) levels are associated with a higher risk of coronary and cerebro vascular disease, independent of total cholesterol or LDL levels. 11/15/2012 Biochemistry for Medics 27
  • 28.
    Additional Risk Factors Stressful lifestyle ("type A" personality);  Obesity - Due to o Hypertension o Diabetes o Hypertriglyceridemia and o Decreased HDL. 11/15/2012 Biochemistry for Medics 28
  • 29.
    Pathogenesis of Atherosclerosis Thecontemporary view of atherogenesis is expressed by the response-to-injury hypothesis. This model views atherosclerosis as a chronic inflammatory response of the arterial wall to endothelial injury.  Lesion progression occurs through interactions of modified lipoproteins, monocyte-derived macrophages, T lymphocytes, and the normal cellular constituents of the arterial wall. 11/15/2012 Biochemistry for Medics 29
  • 30.
    Pathogenesis of Atherosclerosis 1)Endothelial Injury  Initial triggering event in the development of Atherosclerotic lesions  Causes ascribed to endothelial injury in include mechanical trauma, hemodynamic forces, immunological and chemical mechanisms, metabolic agents like chronic hyperlipidemia, homocystine, circulating toxins from systemic infections, viruses, and tobacco products. 11/15/2012 Biochemistry for Medics 30
  • 31.
    Pathogenesis of Atherosclerosis 2.Intimal Smooth Muscle Cell Proliferation  Endothelial injury causes adherence aggregation and platelet release reaction at the site of exposed sub endothelial connective tissue.  Proliferation of intimal smooth muscle cells is stimulated by various mitogens released from platelets adherent at the site of endothelial injury.  These mitogens include platelet derived growth factor (PDGF), fibroblast growth factor, TNF-Ώ.  Proliferation is also facilitated by nitric oxide and endothelin released from endothelial cells. 11/15/2012 Biochemistry for Medics 31
  • 32.
    Pathogenesis of Atherosclerosis 3)Role of Blood Monocytes Though blood monocytes do not possess receptors for normal LDL, LDL does appear in the monocyte cytoplasm to form foam cell. Plasma LDL on entry into the intima undergoes oxidation. Oxidized LDL formed in the intima is readily taken up by scavenger receptor on the monocyte to transform it to a lipid laden foam cell. 11/15/2012 Biochemistry for Medics 32
  • 33.
    11/15/2012 Biochemistry for Medics 33
  • 34.
    Pathogenesis of Atherosclerosis OxidizedLDL stimulates the release of growth factors, cytokines, and chemokines by endothelial cells (EC)and macrophages that increase monocyte recruitment into lesions. Oxidized LDL is cytotoxic to ECs and smooth muscle cells (SMCs )and can induce Endothelial dysfunction. 11/15/2012 Biochemistry for Medics 34
  • 35.
    Pathogenesis of Atherosclerosis 4)Role of Hyperlipidemia Chronic hyperlipidemia in itself may initiate endothelial injury and dysfunction by causing increased permeability.  Increased serum concentration of LDL and VLDL promote formation of foam cells, while high serum concentration of HDL has anti- atherogenic effect. 11/15/2012 Biochemistry for Medics 35
  • 36.
    11/15/2012 Biochemistry for Medics 36
  • 37.
    Progression of Atherosclerosis Fatty Streaks- Fatty streaks are composed of lipid-filled foam cells but are not significantly raised and thus do not cause any disturbance in blood flow  Fatty streaks can appear in the aortas of infants younger than 1 year and are present in virtually all children older than 10 years, regardless of geography, race, sex, or environment.  The relationship of fatty streaks to atherosclerotic plaques is uncertain; although they may evolve into precursors of plaques, not all fatty streaks are destined to become advanced atherosclerotic lesions. 11/15/2012 Biochemistry for Medics 37
  • 38.
    Progression of Atherosclerosis AtheroscleroticPlaque-The key processes in atherosclerosis are intimal thickening and lipid accumulation Atheromatous plaques (also called fibrous or fibro fatty plaques) impinge on the lumen of the artery and grossly appear white to yellow Plaques vary from 0.3 to 1.5 cm in diameter but can coalesce to form larger masses. 11/15/2012 Biochemistry for Medics 38
  • 39.
    Components of Atherosclerotic plaque Atherosclerotic plaques have three principal components: Cells, including SMCs, macrophages, and T cells  ECM, including collagen, elastic fibers, and proteoglycans and Intracellular and extracellular lipid These components occur in varying proportions and configurations in different lesions. 11/15/2012 Biochemistry for Medics 39
  • 40.
    Changes in AtheroscleroticPlaque Atherosclerotic plaques are susceptible to the following pathologic changes with clinical significance:  Rupture, ulceration, or erosion  Hemorrhage  Atheroembolism  Aneurysm formation  Atherosclerosis is a slowly evolving lesion usually requiring many decades to become significant.  However, acute plaque changes (e.g., rupture, thrombosis, or hematoma formation) can rapidly precipitate clinical sequelae (the so-called "clinical horizon“) 11/15/2012 Biochemistry for Medics 40
  • 41.
    Progression of Atherosclerosis 11/15/2012 Biochemistry for Medics 41
  • 42.
    Atherosclerosis- Symptoms Symptomatic atheroscleroticdisease most often involves the arteries supplying the heart, brain, kidneys, and lower extremities. Myocardial infarction (heart attack), cerebral infarction (stroke), aortic aneurysms, and peripheral vascular disease (gangrene of the legs) are the major consequences of atherosclerosis. 11/15/2012 Biochemistry for Medics 42
  • 43.
    Prevention of AtheroscleroticVascular Disease Primary prevention aims at either delaying atheroma formation or encouraging regression of established lesions in persons who have not yet suffered a serious complication of atherosclerosis Secondary prevention is intended to prevent recurrence of events such as myocardial infarction or stroke in symptomatic patients 11/15/2012 Biochemistry for Medics 43
  • 44.
    Prevention of Atherosclerotic VascularDisease Primary prevention of atherosclerosis  Cessation of cigarette smoking  Control of hypertension  Weight loss  Exercise, and lowering total and LDL blood cholesterol levels while increasing HDL (e.g., by diet or through statins).  Statin use may also modulate the inflammatory state of the vascular wall.  Risk factor stratification and reduction should even begin in childhood. 11/15/2012 Biochemistry for Medics 44
  • 45.
    Prevention of Atherosclerotic VascularDisease Secondary prevention involves use of – Aspirin (anti-platelet agent), Statins, and beta blockers (to limit cardiac demand), Surgical interventions (e.g., coronary artery bypass surgery, carotid endarterectomy). These can successfully reduce recurrent myocardial or cerebral events. 11/15/2012 Biochemistry for Medics 45
  • 46.
    Summary  Atherosclerosis isan intima-based lesion organized into a fibrous cap and an atheromatous (gruel-like) core and composed of SMCs, ECM, inflammatory cells, lipids, and necrotic debris.  Atherogenesis is driven by an interplay of inflammation and injury to vessel wall cells.  Atherosclerotic plaques accrue slowly over decades but may acutely cause symptoms due to rupture, thrombosis, hemorrhage, or embolization.  Risk factor recognition and reduction can reduce the incidence and severity of atherosclerosis-related disease. 11/15/2012 Biochemistry for Medics 46